Impact of long-term indwelling JJ stent on renal volume and renal function.


Journal

Minerva urology and nephrology
ISSN: 2724-6442
Titre abrégé: Minerva Urol Nephrol
Pays: Italy
ID NLM: 101777299

Informations de publication

Date de publication:
16 Nov 2022
Historique:
entrez: 16 11 2022
pubmed: 17 11 2022
medline: 17 11 2022
Statut: aheadofprint

Résumé

Data is lacking about long-term impact of JJ stents (JJst) on renal parenchyma. The aim of the study was to assess the evolution of renal parenchyma in patients with JJst indwelling for more than two years, and to find predictive factors for the development of renal atrophy. Consecutive patients with JJst indwelled for more than 24 months, with a history of cancer, were retrospectively included. Replacements of JJst were scheduled every six months, or earlier in case of premature obstruction. Patient characteristics at the time of insertion of JJst, history of indwelling JJst and most recent data (serum creatinine, cancer status, definite JJst removal, renal volume (RV) with3D software) were recorded. With a median follow-up of 4 years, 73 patients were included. The indication of JJst insertion was mostly external compression (65.8%). CT scans were available to assess RV evolution in 66 patients (90.4%). Median shrinkage of RV was higher when JJ stenting was unilateral versus bilateral: -40% (-63; -15) versus -16% (-36; -3), P<0.001. The duration of indwelling JJst was the only statistically significative predictive factor of renal shrinkage in multivariate analysis (OR [CI 95%]: 1.35 [1.10-1.66] P=0.004). Median relative change from baseline in eGFR was -22% (-45%; -5%.). No statistically significant predictive factors of eGFR evolution were found in univariate and multivariate analysis. Unilateral JJst for more than 2 years was associated with a significant shrinkage of renal parenchyma, especially since the duration of the indwelling stent was long.

Sections du résumé

BACKGROUND BACKGROUND
Data is lacking about long-term impact of JJ stents (JJst) on renal parenchyma. The aim of the study was to assess the evolution of renal parenchyma in patients with JJst indwelling for more than two years, and to find predictive factors for the development of renal atrophy.
METHODS METHODS
Consecutive patients with JJst indwelled for more than 24 months, with a history of cancer, were retrospectively included. Replacements of JJst were scheduled every six months, or earlier in case of premature obstruction. Patient characteristics at the time of insertion of JJst, history of indwelling JJst and most recent data (serum creatinine, cancer status, definite JJst removal, renal volume (RV) with3D software) were recorded.
RESULTS RESULTS
With a median follow-up of 4 years, 73 patients were included. The indication of JJst insertion was mostly external compression (65.8%). CT scans were available to assess RV evolution in 66 patients (90.4%). Median shrinkage of RV was higher when JJ stenting was unilateral versus bilateral: -40% (-63; -15) versus -16% (-36; -3), P<0.001. The duration of indwelling JJst was the only statistically significative predictive factor of renal shrinkage in multivariate analysis (OR [CI 95%]: 1.35 [1.10-1.66] P=0.004). Median relative change from baseline in eGFR was -22% (-45%; -5%.). No statistically significant predictive factors of eGFR evolution were found in univariate and multivariate analysis.
CONCLUSIONS CONCLUSIONS
Unilateral JJst for more than 2 years was associated with a significant shrinkage of renal parenchyma, especially since the duration of the indwelling stent was long.

Identifiants

pubmed: 36383182
pii: S2724-6051.22.04975-8
doi: 10.23736/S2724-6051.22.04975-8
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Nicolas Branger (N)

Department of Urology, Institut Paoli Calmettes Cancer Center, Marseille, France - brangern@ipc.unicancer.fr.

Vito Lorusso (V)

Department of Urology, Institut Paoli Calmettes Cancer Center, Marseille, France.

Andrea Pacchetti (A)

Department of Urology, Institut Paoli Calmettes Cancer Center, Marseille, France.

François Lannes (F)

Department of Urology, Institut Paoli Calmettes Cancer Center, Marseille, France.

Davidson Sypre (D)

Department of Urology, Institut Paoli Calmettes Cancer Center, Marseille, France.

Franck Espinosa (F)

Department of Radiology, Institut Paoli Calmettes Cancer Center, Marseille, France.

Christophe Manceau (C)

Department of Radiology, Institut Paoli Calmettes Cancer Center, Marseille, France.

Stanislas Rybikowski (S)

Department of Urology, Institut Paoli Calmettes Cancer Center, Marseille, France.

Serge Brunelle (S)

Department of Radiology, Institut Paoli Calmettes Cancer Center, Marseille, France.

Thomas Maubon (T)

Department of Urology, Institut Paoli Calmettes Cancer Center, Marseille, France.

Naji Salem (N)

Department of Radiation Therapy, Institut Paoli Calmettes Cancer Center, Marseille, France.

Gwénaëlle Gravis (G)

Department of Oncology, Institut Paoli Calmettes Cancer Center, Marseille, France.

Géralidine Pignot (G)

Department of Urology, Institut Paoli Calmettes Cancer Center, Marseille, France.

Jochen Walz (J)

Department of Urology, Institut Paoli Calmettes Cancer Center, Marseille, France.

Classifications MeSH